These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

47 related articles for article (PubMed ID: 913230)

  • 1. Butaclamol in newly admitted chronic schizophrenic patients: a modified fixed-dose dose-range design.
    Clark ML; Costiloe JP; Wood F; Paredes A; Fulkerson FG
    Dis Nerv Syst; 1977 Nov; 38(11):943-7. PubMed ID: 913230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Butaclamol in the treatment of schizophrenia. A standard-controlled clinical trial.
    Nestoros JN; Lehmann HE; Ban TA
    Int Pharmacopsychiatry; 1978; 13(3):138-50. PubMed ID: 355181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of butaclamol in chronic schizophrenic patients.
    Clark ML; Paredes A; Costiloe JP; Wood F
    J Clin Pharmacol; 1977; 17(8-9):529-36. PubMed ID: 19510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of two dose levels of loxapine succinate in chronic schizophrenia.
    Clark ML; Paredes A; Costiloe JP; Fulkerson FG; Wood F
    Dis Nerv Syst; 1977 Jan; 38(1):7-10. PubMed ID: 318984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimal effective dose and relapse--double-blind trial: haloperidol decanoate vs. placebo.
    Eklund K; Forsman A
    Clin Neuropharmacol; 1991; 14 Suppl 2():S7-12; discussion S12-5. PubMed ID: 1684310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparison of 6 different methods for lorazepam withdrawal. A controlled study, hydroxyzine versus placebo].
    Lemoine P; Touchon J; Billardon M
    Encephale; 1997; 23(4):290-9. PubMed ID: 9417395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Butaclamol hydrochloride in newly admitted schizophrenics.
    Hollister LE; Davis KL; Berger PA
    Psychopharmacol Commun; 1975; 1(5):493-500. PubMed ID: 778939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of warm-supplementing kidney yang (WSKY) capsule added on risperidone on cognition in chronic schizophrenic patients: a randomized, double-blind, placebo-controlled, multi-center clinical trial.
    Chen ZH; Wang GH; Wang XP; Chen RY; Wang HL; Yang MH; Huo YX; Mei HB
    Hum Psychopharmacol; 2008 Aug; 23(6):465-70. PubMed ID: 18536066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial.
    Möller HJ; Riedel M; Müller N; Fischer W; Kohnen R
    Pharmacopsychiatry; 2004 Nov; 37(6):270-8. PubMed ID: 15551193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
    Chouinard G; Jones B; Remington G; Bloom D; Addington D; MacEwan GW; Labelle A; Beauclair L; Arnott W
    J Clin Psychopharmacol; 1993 Feb; 13(1):25-40. PubMed ID: 7683702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychomotor performance in healthy young adult volunteers receiving lormetazepam and placebo: a single-dose, randomized, double-blind, crossover trial.
    Fabbrini M; Frittelli C; Bonanni E; Maestri M; Manca ML; Iudice A
    Clin Ther; 2005 Jan; 27(1):78-83. PubMed ID: 15763608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analgesic effects of intranasal butorphanol tartrate administered via a unit-dose device in the dental impaction pain model: a randomized, double-blind, placebo-controlled, parallel-group study.
    Wermeling DP; Grant GM; Lee A; Alexander N; Rudy AC
    Clin Ther; 2005 Apr; 27(4):430-40. PubMed ID: 15922816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma haloperidol levels drawn at neuroleptic threshold doses: a pilot study.
    McEvoy JP; Stiller RL; Farr R
    J Clin Psychopharmacol; 1986 Jun; 6(3):133-8. PubMed ID: 3711363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pimozide in chronic schizophrenic outpatients.
    Clark ML; Huber WK; Hill D; Wood F; Costiloe JP
    Dis Nerv Syst; 1975 Mar; 36(3):137-41. PubMed ID: 1112170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An analysis of safety and tolerability data from controlled, comparative studies of quetiapine in patients with schizophrenia, focusing on extrapyramidal symptoms.
    Timdahl K; Carlsson A; Stening G
    Hum Psychopharmacol; 2007 Jul; 22(5):315-25. PubMed ID: 17542047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension.
    Tzimos A; Samokhvalov V; Kramer M; Ford L; Gassmann-Mayer C; Lim P; Eerdekens M
    Am J Geriatr Psychiatry; 2008 Jan; 16(1):31-43. PubMed ID: 18165460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials.
    Weiden PJ; Cutler AJ; Polymeropoulos MH; Wolfgang CD
    J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S12-9. PubMed ID: 18334908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of oxymorphone immediate release for acute postoperative pain after abdominal surgery: a randomized, double-blind, active- and placebo-controlled, parallel-group trial.
    Aqua K; Gimbel JS; Singla N; Ma T; Ahdieh H; Kerwin R
    Clin Ther; 2007 Jun; 29(6):1000-12. PubMed ID: 17692717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.